Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

49 results about "Gene interaction" patented technology

Gene interactions can result in the alteration or suppression of a phenotype. This can occur when an organism inherits two different dominant genes, for example, resulting in incomplete dominance.

Protein fragment complementation assays for high-throughput and high-content screening

The present invention provides protein fragment complementation assays for drug discovery, in particular to identify compounds that activate or inhibit cellular pathways. Based on the selection of an interacting protein pair combined with an appropriate PCA reporter, the assays may be run in high-throughput or high-content mode and may be used in automated screening of libraries of compounds. The interacting pair may be selected by cDNA library screening; by gene-by-gene interaction mapping; or by prior knowledge of a pathway. Fluorescent and luminescent assays can be constructed using the methods provided herein. The selection of suitable PCA reporters for high-throughput or high-content (high-context) assay formats is described for a diversity of reporters, with particular detail provided for examples of monomeric enzymes and fluorescent proteins. Methods are described for constructing such assays for one or more steps in a biochemical pathway; testing the effects of compounds from combinatorial, natural product, peptide, antibody, nucleic acid or other diverse libraries on the protein or pathway(s) of interest; and using the results of the screening to identify specific compounds that activate or inhibit the protein or pathway(s) of interest. Single-color and multi-color assays are disclosed. Further disclosed are universal expression vectors with cassettes that allow the rapid construction of assays for a large and diverse number of gene / reporter combinations. The development of such assays is shown to be straightforward, providing for a broad, flexible and biologically relevant platform for drug discovery.
Owner:ODYSSEY THERA INC

Protein fragment complementation assays for high-throughput and high-content screening

The present invention provides protein fragment complementation assays for drug discovery, in particular to identify compounds that activate or inhibit cellular pathways. Based on the selection of an interacting protein pair combined with an appropriate PCA reporter, the assays may be run in high-throughput or high-content mode and may be used in automated screening of libraries of compounds. The interacting pair may be selected by cDNA library screening; by gene-by-gene interaction mapping; or by prior knowledge of a pathway. Fluorescent and luminescent assays can be constructed using the methods provided herein. The selection of suitable PCA reporters for high-throughput or high-content (high-context) assay formats is described for a diversity of reporters, with particular detail provided for examples of monomeric enzymes and fluorescent proteins. Methods are described for constructing such assays for one or more steps in a biochemical pathway; testing the effects of compounds from combinatorial, natural product, peptide, antibody, nucleic acid or other diverse libraries on the protein or pathway(s) of interest; and using the results of the screening to identify specific compounds that activate or inhibit the protein or pathway(s) of interest. Single-color and multi-color assays are disclosed. Further disclosed are universal expression vectors with cassettes that allow the rapid construction of assays for a large and diverse number of gene / reporter combinations. The development of such assays is shown to be straightforward, providing for a broad, flexible and biologically relevant platform for drug discovery.
Owner:ODYSSEY THERA INC

Cancer genome and non-specific gene tag-based large-scale drug relocation method

The invention relates to a cancer genome and non-specific gene tag-based large-scale drug relocation method, and discloses a method for expression profile core labels of single human coding gene mutations without organization resource backgrounds through integrating and analyzing large-scale transcriptome data in different cancer types for the first time. On the basis of core labels, the inventionprovides a drug relocation method which aims at the in-vivo environment, is not based on model animals or cells and is capable of comprehensively covering more than 8000 human genome potential targetgenes for the first time, and designs a quantitative index for measuring interaction specificity between drugs and target genes for the first time, so that a drug relocation analysis method for comprehensively analyzing human drug target genes in a large scale is realized and a new way is provided or drug target point design and human disease treatment.
Owner:SHANGHAI INST OF BIOLOGICAL SCI CHINESE ACAD OF SCI

Viruses targeted to hypoxic cells and tissues

The present invention relates to compositions comprising a novel recombinant virus which replicates selectively in cells or tissues that are hypoxic or have an activated HIF pathway. The novel compositions of the invention comprise a recombinant virus genetically engineered to have a hypoxia / HIF-responsive element, or a multiplicity of such elements, operably linked to a promoter which is in turn operably linked to a nucleic acid(s) encoding a peptide(s) which regulates or modulates replication of the virus and / or encode a therapeutic molecule. The invention also includes constructs useful for screening of agents which interact with proteins or genes in the hypoxia-inducible pathway or are jointly translated under hypoxia and animal models useful for monitoring a variety of hypoxic conditions in a non-invasive manner.
Owner:EMORY UNIVERSITY

Individual and cohort pharmacological phenotype prediction platform

PendingCN111742370AIdentification is accurate and validMedical data miningHealth-index calculationSubstance abuserIdiopathic disease
For patients who exhibit or may exhibit primary or comorbid disease, pharmacological phenotypes may be predicted through the collection of panomic, physiomic, environmental, sociomic, demographic, andoutcome phenotype data over a period of time. A machine learning engine may generate a statistical model based on training data from training patients to predict pharmacological phenotypes, includingdrug response and dosing, drug adverse events, disease and comorbid disease risk, drug-gene, drug-drug, and polypharmacy interactions. Then the model may be applied to data for new patients to predict their pharmacological phenotypes, and enable decision making in clinical and research contexts, including drug selection and dosage, changes in drug regimens, polypharmacy optimization, monitoring,etc., to benefit from additional predictive power, resulting in adverse event and substance abuse avoidance, improved drug response, better patient outcomes, lower treatment costs, public health benefits, and increases in the effectiveness of research in pharmacology and other biomedical fields.
Owner:RGT UNIV OF MICHIGAN

Analytic method for predicting body weight increase caused by treating schizophrenia through second-generation antipsychotic based on polygene combination interactive effect

The invention discloses an analysis method for predicting body weight increase caused by treating schizophrenia through a second-generation antipsychotic based on the polygene combination interactiveeffect. The method comprises the steps that a sample is prepared for collecting peripheral blood of a patient with body weight increase caused by treating schizophrenia through the second-generation antipsychotic, a hypotonic salt fractionation method is used for extracting a genome DNA sample; a MODLI-TOF flight mass spectrum detecting method is used for performing genetic typing of a 5-HT2CR gene, a histamine 1 receptor gene, an oxytocin gene, an NPY / R gene, a Leptin gene, an adiponectin gene, an FGF21 gene and a FGF23 gene; data analysis and extraction are performed, instrument original data is aligned, data with no noise interference for statistic analysis is obtained, a generalized multi-factor dimension reduction method is used for performing the quantitative trait gene-gene interaction effect, crossed verification is further applied, and the gene interaction effect is used for predicting body weight increase. By adopting the generalized multi-factor dimension reduction method, the continuous ending variable is processed, covariance is introduced, and the method has the advantages of greatly enlarging the application range and greatly increasing the prediction accuracy.
Owner:SECOND AFFILIATED HOSPITAL OF XINJIANG MEDICAL UNIV

Plants with reduced expression of phosphatase type 2c gene for enhanced pathogen resistance

The present invention relates to a method for down regulating an Arabidopsis protein phosphatase type 2C gene, referred to as “defense-associated protein phosphatase type 2C one” (DAPP1) that functions as a negative regulator of a plant defense pathway by contacting the gene or gene mRNA with an interfering nucleotide sequence that interacts with the gene and reducing expression thereof. Plants including such interfering nucleotide sequence exhibit increased disease resistance to pathogen even in the absence of R genes. Close homologs of DAPP1 exist in multiple crop species, and as such, the controlled down-regulation of homologous genes in a variety of crop species will enhance disease resistance of target crop species to pathogens.
Owner:UNIV OF MARYLAND

Method for screening micro ribonucleic acid (microRNA) target gene based on natural language processing system

InactiveCN102375840AIdentification work is easySolve the problem of predicting too many and too many microRNA target genesSpecial data processing applicationsNODALResearch Object
The invention discloses a bioinformatics method capable of screening a micro ribonucleic acid (microRNA) target gene from the existing literature by using a computer natural language processing system, which can eliminate complicated steps of a middle experiment and locking the target gene directly so as to bring convenience to further experiment verification. The method mainly comprises the following steps of: 1, selecting a specific development object and the microRNA; 2, introducing a literature excavation technology, and searching a relative gent; 3, performing target gene prediction on the microRNA, and settling into a list; 4, integrating gene lists in the steps 3 and 4, and constructing a gene interaction relationship network; 5, analyzing the connectivity of the gene in the step 4, searching a node gene, and screening a key target gene of the microRNA out; and 6, performing experiment verification.
Owner:浙江中医药大学附属第一医院

Application of rice tRNA isopentenyl transferase gene OsIPT9 in brown planthopper resistance of rice

The invention discloses an application of a rice tRNA isopentenyl transferase gene OsIPT9 in brown planthopper resistance of rice, which belong to the technical field of plant genetic engineering. TheOsIPT9 has an amino acid sequence as shown in SEQ ID No. 1, the nucleotide sequence of the OsIPT9 is as shown in SEQ ID No. 2, and the ORF sequence of the OsIPT9 is as shown in SEQ ID No. 3. The OsIPT9 is transferred into Nipponbare which is sensitive to the brown planthopper through agrobacterium-mediated genetic transformation, and the resistance of overexpressed plants to the brown planthopperis enhanced; meanwhile, in a resistant material NIP-Bph6-NIL, the OsIPT9 is knocked out by utilizing a CRISPR / Cas9 technology, so that the resistance of the plant to the brown planthopper is remarkably reduced. The gene disclosed by the invention provides a good theoretical basis for researching gene interaction between rice and brown planthopper, and has reference significance for researching gene molecular functions and breeding.
Owner:WUHAN UNIV +1

Microarrays to screen regulatory genes

Microarray technology allows the multiple parallel processing of information generated from matrices of huge numbers of loci on a solid substrate, which is useful in the gathering of gene signatures defining specific biological states. An approach has been developed to facilitate this process wherein genes of the same regulatory modality are selected. The transcriptional regulation of these genes is related to the same control element. Primers specific for the regulatory genes are selected, based on minimum cross-reactivity with other genes, using known gene data banks. PCR products of selected regions of known genes either binding to this sequence or whose expression is dependent on this binding, as well as genes interacting with the regulatable genes and control genes, referred to as “amplicons” or “gene cDNA fragments” of between about 450 and 1000 nucleotide bases in length, are obtained from a total RNA pool. These amplicons are arrayed on a nylon membrane or other appropriate microchip susbstrate, which is then used as a regulatory gene-specific microarray that is hybridized with sample. Sample will typically be the mRNA obtained from cells associated with a particular state (examples include age or exposure to conditions such as outspace, low gravity), disease (such as cancer or an infection), or disorder (such as a genetic defect or trauma). The transcriptionally regulated profile of regulatory gene-related genes specific to a given cultured cell sample is then determined using a software based analysis of the amount of hybridization which is detected. This information is useful in determining drug targets, markers associated with the disease state (either the presence or absence, or the extent of the disease), or the response of the disease state to drugs or other treatments.
Owner:LOUISVILLE RES FOUND UNIV OF

Method and system for predicting interaction between miRNA and gene based on multi-relational graph convolutional network

PendingCN114093422ARich forecasting meansFully capture the structureNeural architecturesSequence analysisInformation networksHeterogeneous network
The invention discloses a method and a system for predicting interaction between miRNA and a gene based on a multi-relational graph convolutional network. The method comprises: constructing a heterogeneous information network of miRNA and genes, and learning network topology features of nodes by using a multi-relational graph convolutional network based on the heterogeneous network; meanwhile, capturing effective characteristics of the gene sequence by using a recurrent neural network; and finally, combining network topology characteristics with sequence characteristics, and calculating an association prediction score of the miRNA-gene pair by using the obtained miRNA and gene embedding. According to the method, manual feature construction is not needed in the implementation process, representation learning is combined, the advantages of the multi-relation graph convolutional network are fully utilized, effective gene sequence information is mined, and feature representation of miRNA and gene nodes is better captured. Experimental results show that the MRMTI is superior to other comparison methods in the aspect of association prediction of miRNA and genes, and has good prediction performance.
Owner:HUNAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products